[Potential Value of Neoadjuvant Immunochemotherapy in Patients with Driver Gene-positive Non-small Cell Lung Cancer].
Under the premise of not exacerbating adverse effects, neoadjuvant immunochemotherapy achieved superior rates of MPR and pCR, with long-term survival comparable to targeted therapy.
Authors
- Xingxiang Pu (ORCID: https://orcid.org/0000-0002-2743-7080)
- Zihan Wei (ORCID: https://orcid.org/0000-0001-9234-3497)
- Xiang Yan
- Yu Zhou (ORCID: https://orcid.org/0000-0003-3230-8395)
Institutions
- Central South University (CN)
- Peking University (CN)
- Hunan Cancer Hospital (CN)
- Peking University People's Hospital (CN)
Publication Details
- Journal
- PubMed
- Published
- 2024-09-20
- DOI
- https://doi.org/10.3779/j.issn.1009-3419.2024.101.24
- Citations
- 2
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article